AVITA Medical (ASX:AVH) Short-Term Debt : A$0.00 Mil (As of Sep. 2024)

View and export this data going back to 1993. Start your Free Trial

What is AVITA Medical Short-Term Debt?

AVITA Medical's Short-Term Debt for the quarter that ended in Sep. 2024 was A$0.00 Mil.

AVITA Medical Short-Term Debt Historical Data

The historical data trend for AVITA Medical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Short-Term Debt Chart

AVITA Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

AVITA Medical Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

AVITA Medical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

AVITA Medical Short-Term Debt Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (ASX:AVH) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

RCEL:USA AVHHL:USA 51KA:Germany 51KB:Germany

Address

28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

AVITA Medical Headlines

No Headlines